Skip to main content
    S

    Sarepta Therapeutics Inc (SRPT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $15.13
    -0.94 (-5.85%)

    Market Cap: $1.72B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Sarepta Therapeutics Inc (SRPT) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Sarepta Therapeutics (SRPT) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, Sarepta Therapeutics reported EPS of -$0.10, below the $0.17 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    46%(18/39)
    Avg Surprise
    -5.32%

    Upcoming Estimates

    Reports Feb 23, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.37
    Range-$1.53 - $0.21
    24 analysts
    Revenue Consensus
    $360.44M
    Range$294.75M - $400.47M
    22 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.44
    Range-$0.02 - $0.96
    6 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.78-43.9%
    60d ago$0.75-41.6%
    30d ago$0.78-43.9%
    7d ago$0.73-40.6%
    Current$0.44
    Revenue Consensus
    $357.09M
    Range$320.70M - $383.90M
    11 analysts

    Next Report

    SRPT has an expected report date of Feb 23, 2027.

    SRPT Earnings Call

    The latest SRPT earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, SRPT beat 18 and missed 21. Revenue for the quarter ended Sep 30, 2026 was $381.35M, down 4.5% from $399.36M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.10$0.17-$0.06 - $1.06-158.82%MissN/A100 up, 1 downNov 5, 2026$381.35M
    Jun 30, 2026$0.42$0.34$0.11 - $0.79+23.53%Beat-79.2%91 up, 0 downAug 5, 2026$401.25M
    Mar 31, 2026$3.16$1.05-$0.39 - $2.58+200.95%BeatN/A105 up, 2 downMay 6, 2026$730.80M
    Dec 31, 2025-$3.58-$1.05-$1.88 - $0.37-240.95%Miss-288.4%115 up, 2 downFeb 25, 2026$442.93M
    Sep 30, 2025-$0.13-$0.37-$1.57 - $0.56+64.86%Beat-121.0%120 up, 5 downNov 3, 2025$399.36M
    Jun 30, 2025$2.02$1.16$0.81 - $1.96+74.14%Beat+359.1%137 up, 5 downAug 6, 2025$611.09M
    Mar 31, 2025-$3.42-$0.65-$3.95 - $3.14-426.15%Miss-568.5%121 up, 4 downMay 6, 2025$744.86M
    Dec 31, 2024$1.90$2.06$1.32 - $2.64-7.78%Miss+304.3%115 up, 0 downFeb 26, 2025$658.41M
    Sep 30, 2024$0.62$0.37-$0.81 - $0.68+67.57%Beat+67.6%141 up, 1 downNov 6, 2024$467.17M
    Jun 30, 2024$0.44$0.47N/A-6.38%MissN/A131 up, 0 downAug 7, 2024$362.93M
    Mar 31, 2024$0.73$0.41N/A+78.05%BeatN/A131 up, 0 downMay 1, 2024$413.46M
    Dec 31, 2023$0.47$0.01-$1.03 - $0.61N/AN/AN/A172 up, 3 downFeb 28, 2024$396.78M
    Sep 30, 2023$0.37-$0.49-$1.95 - -$0.41+175.51%BeatN/A114 up, 0 downNov 1, 2023$331.82M
    Jun 30, 2023-$0.85-$1.00N/A+15.00%BeatN/A131 up, 1 downAug 2, 2023$261.24M
    Mar 31, 2023-$0.97-$0.83-$1.61 - -$0.82-16.87%MissN/A132 up, 0 downMay 2, 2023$253.50M
    Dec 31, 2022-$1.24-$1.35-$1.85 - -$0.92+8.15%BeatN/A132 up, 0 downFeb 28, 2023$258.43M
    Sep 30, 2022-$0.80-$0.74N/A-8.11%MissN/A133 up, 0 downNov 2, 2022$230.27M
    Jun 30, 2022-$1.18-$0.60N/A-96.67%MissN/A120 up, 1 downAug 2, 2022$233.49M
    Mar 31, 2022-$0.56-$1.03-$1.72 - -$0.58+45.63%BeatN/A141 up, 0 downMay 4, 2022$210.83M
    Dec 31, 2021-$1.42-$1.13-$1.99 - -$0.28-25.66%MissN/A141 up, 0 downMar 1, 2022$201.46M
    Sep 30, 2021-$0.19-$1.52-$2.34 - -$1.32+87.50%BeatN/A14N/ANov 3, 2021$189.41M
    Jun 30, 2021-$1.52-$1.29-$2.06 - -$0.19-17.83%MissN/A13N/AAug 4, 2021$164.09M
    Mar 31, 2021-$1.54-$1.57-$2.50 - -$0.35+1.91%BeatN/A14N/AMay 5, 2021$146.93M
    Dec 31, 2020-$2.40-$1.78-$2.18 - -$0.31-34.83%MissN/A16N/AMar 1, 2021$145.14M
    Sep 30, 2020-$1.42-$1.40-$2.45 - -$0.89-1.43%MissN/A20N/ANov 5, 2020$143.92M
    Jun 30, 2020-$1.51-$1.31-$3.24 - -$1.06-15.27%MissN/A18N/AAug 5, 2020$137.36M
    Mar 31, 2020-$0.23-$1.88-$3.11 - -$0.78+87.77%BeatN/A16N/AMay 6, 2020$113.67M
    Dec 31, 2019-$1.57-$1.27N/A-23.62%MissN/A18N/AFeb 26, 2020$100.11M
    Sep 30, 2019-$1.14-$0.92N/A-23.91%MissN/A19N/ANov 7, 2019$99.04M
    Jun 30, 2019-$0.83-$0.77N/A-7.79%MissN/A18N/AAug 7, 2019$94.67M
    Mar 31, 2019-$0.75-$0.81-$3.63 - -$0.65+7.41%BeatN/A19N/AMay 8, 2019$87.01M
    Dec 31, 2018-$2.05-$1.02-$1.44 - -$0.57-100.98%MissN/A17N/AFeb 27, 2019$84.42M
    Sep 30, 2018-$0.56-$0.49-$1.70 - -$0.34-14.29%MissN/A19N/AOct 24, 2018$78.49M
    Jun 30, 2018-$0.43-$0.33N/A-30.30%MissN/A15N/AAug 8, 2018$73.53M
    Mar 31, 2018-$0.28-$0.24N/A-16.67%MissN/A15N/AMay 3, 2018$64.60M
    Dec 31, 2017-$0.37-$0.32-$0.56 - -$0.17-15.63%MissN/A16N/AMar 1, 2018$57.28M
    Sep 30, 2017-$0.33-$0.77N/A+57.14%BeatN/AN/AN/AOct 25, 2017$45.95M
    Jun 30, 2017-$0.65-$0.78N/A+16.67%BeatN/AN/AN/AJul 19, 2017$35.01M
    Mar 31, 2017-$0.60-$0.94N/A+36.17%BeatN/AN/AN/AApr 27, 2017$16.34M
    Dec 31, 2016-$0.87-$1.33N/A+34.59%BeatN/AN/AN/AFeb 28, 2017$5.42M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$5.11, after $3.69 the year before. It was -$4.16 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$5.11-238.5%
    Dec 31, 2024$3.69N/A
    Dec 31, 2023-$0.98N/A
    Dec 31, 2022-$3.78N/A
    Dec 31, 2021-$4.67N/A
    Dec 31, 2020-$5.56N/A
    Dec 31, 2019-$4.29N/A
    Dec 31, 2018-$3.32N/A
    Dec 31, 2017-$1.95N/A
    Dec 31, 2016-$4.16N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 10,000 words across 22 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 202610,30522
    2026Q2Jun 30, 20269,47726
    2026Q1Mar 31, 20267,35717
    2025Q4Dec 31, 202512,34025
    2025Q3Sep 30, 20259,56825
    2025Q2Jun 30, 20258,72916
    2025Q1Mar 31, 202510,26523
    2024Q4Dec 31, 202412,40126

    2026Q3 Earnings Call

    Opening remarks

    Tam Thornton Senior Director of Investor Relations Thank you, Michelle, and thank you all for joining today's call. Earlier this afternoon, we released our financial results for the third quarter of 2026. The press release, along with our presentation slides and supplementary information, are available on the investor section of our company website. We plan to file our Form 10-Q for the quarter today with the SEC. Joining me on the call today are Mike Severino, our Chief Executive Officer, Dr. Louise Rodino-Klapac, President of Research and Development and Technical Operations, Patrick Moss, our Chief Commercial Officer, and Ryan Wong, our Chief Financial Officer. Additionally, joining us in the Q&A portion of the call are Ian Estepan, President and Chief Operations Officer, and Dr. James Richardson, our Chief Medical Officer. Before we begin the formal remarks, I would like to note that during this call, we will be making a number of forward-looking statements. Please refer to slide two of our presentation to view the formal text of these safe harbor statements. These statements involve varying risks and uncertainties, many of which are beyond Sarepta's control. Actual results could materially differ from these forward-looking statements, and such risks can adversely affect our business, our results of operations, and the trading price for Sarepta's common stock. We strongly encourage all listeners to review the company's most recent SEC filings for a detailed description of these applicable risks. Sarepta explicitly states that it does not undertake any obligation to publicly update or revise its forward-looking statements or financial projections based on subsequent events. Furthermore, please note that we will discuss non-GAAP financial measures during today's webcast. Complete descriptions and reconciliations of our GAAP to non-GAAP financial measures are included in today's press release and the accompanying slide presentation available to investors on our website. With that, I will now turn the call over to our CEO, Mike Severino.

    Mike Severino CEO Thanks, Tam. Good afternoon, everyone, and thank you for joining us. It has been a little over 90 days since I joined Sarepta, and I want to begin by sharing a few reflections from that time and how they are shaping my priorities for the company. What initially attracted me to Sarepta was a combination that I believe is unique in biotech at our scale: an established commercial business and leadership position in Duchenne, a promising pipeline with the potential to produce differentiated medicines, and the financial strength to invest in that pipeline from our own commercial cash flows. After my first 90 days, I believe those fundamental strengths are very much intact.

    Frequently Asked Questions About SRPT

    When is Sarepta Therapeutics's next earnings date?

    Sarepta Therapeutics's next earnings report is expected for Feb 23, 2027.

    Did SRPT beat earnings estimates last quarter?

    No. Sarepta Therapeutics reported EPS of -$0.10 for the quarter ended Sep 30, 2026, below the $0.17 estimate by 158.82%.

    What EPS do analysts expect from SRPT next quarter?

    The consensus EPS estimate for Sarepta Therapeutics for the quarter ending Dec 31, 2026 is -$0.37 from 24 analysts, with estimates from -$1.53 to $0.21.

    How often does SRPT beat earnings estimates?

    Sarepta Therapeutics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -58.78%.